Pieris Pharmaceuticals (PIRS) News Today → The only AI company to buy (From Porter & Company) (Ad) Free PIRS Stock Alerts $9.76 -0.72 (-6.87%) (As of 01:51 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 23, 2024 | americanbankingnews.comPieris Pharmaceuticals (NASDAQ:PIRS) Coverage Initiated at StockNews.comMay 17, 2024 | investorplace.comPIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q1 2024May 15, 2024 | washingtonpost.comPieris Pharmaceuticals: Q1 Earnings SnapshotApril 24, 2024 | marketbeat.comPieris Pharmaceuticals (NASDAQ:PIRS) Shares Gap Down to $12.00Pieris Pharmaceuticals (NASDAQ:PIRS) Shares Gap Down to $12.00April 23, 2024 | marketbeat.comPieris Pharmaceuticals (NASDAQ:PIRS) Sees Large Volume IncreasePieris Pharmaceuticals (NASDAQ:PIRS) Sees Unusually-High Trading VolumeApril 23, 2024 | marketbeat.comTrading was temporarily halted for "PIRS" at 07:04 PM with a stated reason of "News pending."April 1, 2024 | msn.comAvalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72MMarch 28, 2024 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty PotentialMarch 27, 2024 | finance.yahoo.comPieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty PotentialMarch 19, 2024 | finance.yahoo.comPIRS Apr 2024 2.500 callFebruary 10, 2024 | investing.comPieris Pharmaceuticals Inc (PIRS)February 1, 2024 | finance.yahoo.comPieris Pharmaceuticals, Inc. (PIRS)December 18, 2023 | finance.yahoo.comInvestors Don't See Light At End Of Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Tunnel And Push Stock Down 27%November 20, 2023 | investing.comPieris Pharmaceuticals Inc (PIRS) Earnings Dates & ReportsNovember 4, 2023 | morningstar.comPieris Pharmaceuticals Inc PIRSSeptember 25, 2023 | finance.yahoo.comPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's WhyAugust 24, 2023 | finance.yahoo.comIs Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive AnalysisAugust 23, 2023 | finance.yahoo.comPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should KnowAugust 18, 2023 | msn.comPieris (PIRS) Up On Receiving Milestone Payment From PartnerAugust 17, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology BispecificJuly 19, 2023 | finance.yahoo.comPieris (PIRS) Pursues Strategic Alternatives, Stock RisesJuly 19, 2023 | markets.businessinsider.comPieris Pharma Cuts Around 70% Workforce; Plans Strategic OptionsJuly 18, 2023 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Provides Strategic Update and Announces RestructuringJuly 18, 2023 | finance.yahoo.comWhy Pieris Pharmaceuticals Shares Shooting Higher Today?July 18, 2023 | finance.yahoo.comPieris Pharmaceuticals Provides Strategic Update and Announces RestructuringJuly 18, 2023 | marketbeat.comTrading was temporarily halted for "PIRS" at 09:07 AM with a stated reason of "News pending."July 13, 2023 | fool.comPieris Pharmaceuticals (NASDAQ: PIRS)June 21, 2023 | msn.comWhy Are Pieris Pharmaceuticals Shares Tanking TodayJune 21, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology StudyJune 21, 2023 | marketbeat.comTrading was temporarily halted for "PIRS" at 06:06 AM with a stated reason of "News pending."June 11, 2023 | finance.yahoo.comWe're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn RateJune 2, 2023 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare ConferenceJune 2, 2023 | finance.yahoo.comPieris Pharmaceuticals to Present at Jefferies 2023 Healthcare ConferenceMay 22, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International ConferenceMay 21, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International ConferenceMay 15, 2023 | finance.yahoo.comPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts SubstantiallyMay 12, 2023 | seekingalpha.comPieris Pharmaceuticals GAAP EPS of -$0.18 misses by $0.04, revenue of $1.94M misses by $4.57MMay 11, 2023 | finance.yahoo.comPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call TranscriptMay 10, 2023 | msn.comRecap: Pieris Pharmaceuticals Q1 EarningsMay 10, 2023 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business UpdatesMay 10, 2023 | finance.yahoo.comPieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business UpdatesMay 9, 2023 | msn.comPreview: Pieris Pharmaceuticals's EarningsMay 5, 2023 | finance.yahoo.comPieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shares Lagging The Industry But So Is The BusinessMay 4, 2023 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of ElarekibepMay 4, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)May 2, 2023 | finance.yahoo.comPieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023April 17, 2023 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa At 2023 AACR Annual MeetingApril 17, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual MeetingApril 1, 2023 | finance.yahoo.comPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call TranscriptMarch 31, 2023 | finance.yahoo.comPieris Pharmaceuticals Full Year 2022 Earnings: US$0.45 loss per share (vs US$0.71 loss in FY 2021) Get Pieris Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Who are Nvidia’s New Silent Partners? (Ad)Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself. I call these Nvidia’s “Silent Partners.” PIRS Media Mentions By Week PIRS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PIRS News Sentiment▼1.250.92▲Average Medical News Sentiment PIRS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PIRS Articles This Week▼30▲PIRS Articles Average Week Get Pieris Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Rockwell Medical News Anebulo Pharmaceuticals News BioLineRx News Kezar Life Sciences News Equillium News Eagle Pharmaceuticals News CASI Pharmaceuticals News Ocuphire Pharma News Kronos Bio News Aadi Bioscience News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PIRS) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesThe only AI company to buyPorter & CompanyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDigitizing the $11T commodities sector with one tiny stockResource Stock DigestBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
